These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 27692131)

  • 1. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R;
    Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
    J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
    Kempsford RD; Oliver A; Bal J; Tombs L; Quinn D
    Respir Med; 2013 Dec; 107(12):1873-80. PubMed ID: 24200619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term effects of fluticasone furoate/vilanterol in exercising asthmatic adolescents: A randomized and open label trial.
    Bar-Yoseph R; Gur M; Zuckerman S; Gut G; Hanna M; Toukan Y; Nir V; Masarweh K; Bentur L
    Basic Clin Pharmacol Toxicol; 2021 Nov; 129(5):369-375. PubMed ID: 34359097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R; Allen A; Bareille P; Hamilton M; Cheesbrough A
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI; Bateman ED; Woodcock A; Toler WT; Forth R; Jacques L; Nunn C; O'Byrne PM
    J Asthma; 2015; 52(10):1073-83. PubMed ID: 26291137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
    Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
    Zheng J; de Guia T; Wang-Jairaj J; Newlands AH; Wang C; Crim C; Zhong N
    Curr Med Res Opin; 2015 Jun; 31(6):1191-200. PubMed ID: 25830381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.